Crestline Management LP Acquires 67,137 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Crestline Management LP increased its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 57.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 184,818 shares of the company's stock after purchasing an additional 67,137 shares during the quarter. Crestline Management LP owned approximately 0.18% of Dyne Therapeutics worth $4,354,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. KBC Group NV grew its stake in Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company's stock valued at $74,000 after acquiring an additional 978 shares in the last quarter. Summit Investment Advisors Inc. grew its stake in Dyne Therapeutics by 9.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock valued at $203,000 after acquiring an additional 721 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in Dyne Therapeutics during the 4th quarter valued at about $257,000. Magnetar Financial LLC purchased a new position in Dyne Therapeutics during the 4th quarter valued at about $263,000. Finally, E Fund Management Co. Ltd. grew its stake in Dyne Therapeutics by 11.8% during the 4th quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock valued at $279,000 after acquiring an additional 1,249 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.

Wall Street Analysts Forecast Growth

DYN has been the topic of several research analyst reports. JPMorgan Chase & Co. lowered their target price on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st. Chardan Capital reaffirmed a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a research note on Friday. Scotiabank started coverage on Dyne Therapeutics in a research note on Friday, March 7th. They set a "sector outperform" rating and a $50.00 target price on the stock. HC Wainwright lowered their price target on Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a research note on Friday. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $45.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $46.85.

Dyne Therapeutics Price Performance

DYN traded up $1.56 on Monday, hitting $12.97. The company had a trading volume of 1,922,259 shares, compared to its average volume of 1,648,691. Dyne Therapeutics, Inc. has a 1-year low of $6.36 and a 1-year high of $47.45. The stock has a market cap of $1.47 billion, a price-to-earnings ratio of -3.64 and a beta of 1.19. The company's fifty day moving average price is $10.37 and its 200 day moving average price is $17.98.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). On average, sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insider Transactions at Dyne Therapeutics

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the sale, the insider now directly owns 199,087 shares in the company, valued at approximately $2,777,263.65. The trade was a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 6,237 shares of company stock worth $77,760 over the last three months. 14.14% of the stock is currently owned by insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.